Latest Commercialisation News

Page 127 of 189
Cleo Diagnostics reported a $4 million loss for FY2025 while making significant strides toward FDA approval of its novel ovarian cancer blood test. The company is progressing clinical trials and scaling manufacturing in preparation for market entry.
Ada Torres
Ada Torres
26 Aug 2025
Race Oncology Limited reported a significantly reduced loss for FY2025, driven by key clinical trial progress and strategic leadership changes. The company advances its RC220 program with promising Phase 1 dosing milestones and strengthens its governance to support future growth.
Ada Torres
Ada Torres
26 Aug 2025
Hazer Group Limited reported a 124% surge in revenues to $8.5 million for FY25, driven by government grants, while cutting its net loss by 60%. The company advanced its proprietary methane pyrolysis technology, secured a strategic alliance with KBR, and made progress on key projects in Canada and Japan.
Maxwell Dee
Maxwell Dee
26 Aug 2025
Starpharma reports a significant 183% jump in FY25 revenue to $4.9 million, alongside a 31% reduction in losses and a solid cash position of $15.4 million. The biotech firm’s progress underscores growing momentum in its dendrimer technology pipeline.
Ada Torres
Ada Torres
26 Aug 2025
Victory Metals secures $11.5 million through a strategic placement to accelerate drilling and development at its North Stanmore heavy rare earth project, reinforcing its position as Australia’s leading rare earths explorer.
Maxwell Dee
Maxwell Dee
26 Aug 2025
Calix Limited reported a 17% rise in product and services revenue for FY25, driven by its Magnesia and Leilac businesses, alongside a 23% reduction in operating expenses. The company extended its cash runway to 18 months, supported by a $21 million equity raise, while progressing key decarbonisation projects.
Victor Sage
Victor Sage
26 Aug 2025
Rhythm Biosciences has completed critical validation of its ColoSTAT colorectal cancer assay and submitted it for ISO15189 accreditation, paving the way for commercialisation. The test demonstrated strong clinical performance, highlighting its potential as a non-invasive diagnostic tool.
Ada Torres
Ada Torres
26 Aug 2025
Centrepoint Alliance has reported a robust FY25 with 13% revenue growth and a 30% increase in profit before tax, driven by organic adviser expansion, strategic acquisitions, and pioneering technology investments including AI and cybersecurity.
Claire Turing
Claire Turing
26 Aug 2025
Centrepoint Alliance has reported a robust FY25 financial performance, surpassing earnings guidance with a 16% rise in EBITDA and a 30% jump in pre-tax profits. The company also declared a 1.75 cent final dividend and advanced its technology and advisory services.
Claire Turing
Claire Turing
26 Aug 2025
Bio-Gene Technology Limited reported a net loss of AUD 2.58 million for FY2025 while making significant strides in developing its bio-insecticides Flavocide and Qcide, securing US Department of Defense grants and expanding global partnerships.
Ada Torres
Ada Torres
26 Aug 2025
Nanosonics delivered a robust FY25 with 17% revenue growth and a 72% jump in profit before tax, propelled by next-gen trophon devices and advancing CORIS commercialisation.
Ada Torres
Ada Torres
26 Aug 2025
Premier1 Lithium has announced its first inferred mineral resource at the Wadgingarra gold project, marking a significant step towards commercial gold production with promising expansion potential.
Maxwell Dee
Maxwell Dee
26 Aug 2025